Israel
· Delayed Price · Currency is ILS · Price in ILA Lineage Cell Therapeutics Statistics
Total Valuation
TLV:LCTX has a market cap or net worth of ILS 1.38 billion. The enterprise value is 1.22 billion.
| Market Cap | 1.38B |
| Enterprise Value | 1.22B |
Important Dates
The last earnings date was Thursday, March 5, 2026.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 242.33M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +14.95% |
| Shares Change (QoQ) | +3.63% |
| Owned by Insiders (%) | 5.13% |
| Owned by Institutions (%) | 21.72% |
| Float | 180.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 29.84 |
| PB Ratio | 10.02 |
| P/TBV Ratio | 199.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.01 |
| EV / Sales | 27.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -19.62 |
Financial Position
The company has a current ratio of 5.20, with a Debt / Equity ratio of 0.06.
| Current Ratio | 5.20 |
| Quick Ratio | 4.99 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.12 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -105.30% and return on invested capital (ROIC) is -21.73%.
| Return on Equity (ROE) | -105.30% |
| Return on Assets (ROA) | -12.06% |
| Return on Invested Capital (ROIC) | -21.73% |
| Return on Capital Employed (ROCE) | -21.52% |
| Weighted Average Cost of Capital (WACC) | 13.84% |
| Revenue Per Employee | 627,088 |
| Profits Per Employee | -2.74M |
| Employee Count | 74 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -16.83M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +195.02% in the last 52 weeks. The beta is 1.76, so TLV:LCTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.76 |
| 52-Week Price Change | +195.02% |
| 50-Day Moving Average | 535.45 |
| 200-Day Moving Average | 453.95 |
| Relative Strength Index (RSI) | 53.64 |
| Average Volume (20 Days) | 8,078 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TLV:LCTX had revenue of ILS 46.40 million and -202.54 million in losses. Loss per share was -0.89.
| Revenue | 46.40M |
| Gross Profit | 45.94M |
| Operating Income | -69.43M |
| Pretax Income | -218.85M |
| Net Income | -202.54M |
| EBITDA | -67.20M |
| EBIT | -69.43M |
| Loss Per Share | -0.89 |
Balance Sheet
The company has 177.83 million in cash and 7.71 million in debt, giving a net cash position of 170.12 million.
| Cash & Cash Equivalents | 177.83M |
| Total Debt | 7.71M |
| Net Cash | 170.12M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 138.19M |
| Book Value Per Share | 0.58 |
| Working Capital | 152.35M |
Cash Flow
In the last 12 months, operating cash flow was -60.31 million and capital expenditures -1.66 million, giving a free cash flow of -61.98 million.
| Operating Cash Flow | -60.31M |
| Capital Expenditures | -1.66M |
| Free Cash Flow | -61.98M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 99.00% |
| Operating Margin | -149.62% |
| Pretax Margin | -471.61% |
| Profit Margin | n/a |
| EBITDA Margin | -144.82% |
| EBIT Margin | -149.62% |
| FCF Margin | n/a |
Dividends & Yields
TLV:LCTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.95% |
| Shareholder Yield | -14.95% |
| Earnings Yield | -14.63% |
| FCF Yield | -4.48% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |